X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Baclofen,Naltrexone,Sorbitol API
Therapeutic Area: Neurology Product Name: PXT3003
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Alpha Blue Ocean
Deal Size: $96.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 10, 2021
Details:
This financing agreement for up to 81 million euros will enable Pharnext to strengthen its cash position and continue to develop its pivotal Phase III clinical trial of PXT3003, the PREMIER trial, in Charcot-Marie-Tooth disease type 1A (CMT1A).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Baclofen,Naltrexone,Sorbitol API
Therapeutic Area: Neurology Product Name: PXT3003
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2021
Details:
The new results announced today continue to show sustained treatment benefits for CMT1A patients treated with PXT3003 at High Dose (‘HD’) in the PLEO-CMT-FU Period 2 trial with a data readout at 54 months of total trial time (double-blind + open-label).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
